Accessibility Menu
Clinuvel Pharmaceuticals logo

Clinuvel Pharmaceuticals(OTC) CLVLF

Current Price$6.10
Market Cap$307.51MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2003)+2,693%
5 Year-69%
1 Year-23%
1 Month+0%
Clinuvel Pharmaceuticals last closing stock price
MetricPriceDate
Last closeUSD 6.102026-07-23
Clinuvel Pharmaceuticals stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+0%USD 6.102026-06-30
1 month+0%USD 6.102026-06-10
3 month-2.71%USD 6.272026-04-22
Year to date-20.78%USD 7.702025-12-12
1 year-23.41%USD 7.962025-07-23
3 year-49.4%USD 12.062023-07-19
5 year-69.13%USD 19.762021-07-19
Since inception+2,693.16%USD 0.222003-06-24

Clinuvel Pharmaceuticals Financials at a Glance

Market Cap

$307.51MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

A$187.86M

Net Income (TTM)

A$71.31M

EPS (TTM)

$0.41

P/E Ratio

14.65

Dividend

$0.03

Beta (Volatility)

0.10 (Low)

Price

$6.10

Volume

14

Open

$6.10

Previous Close

$6.10

Daily Range

$6.10 - $6.10

52-Week Range

$6.10 - $8.60

Estimated Earnings Date

Sep 1, 2026

CLVLF News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Clinuvel Pharmaceuticals

Clinuvel Pharmaceuticals Limited is an Australian biopharmaceutical company focused on developing and marketing innovative therapeutic solutions for patients with severe genetic and metabolic conditions. Established in 1987, the company operates globally, with a primary emphasis on its flagship product, SCENESSE, which provides photoprotection for individuals suffering from erythropoietic protoporphyria (EPP).

Products and Services
  • SCENESSE: A systemic photoprotective medication for EPP patients
  • CUV9900: An alpha-melanocyte stimulating hormone analogue in development
  • Parvysmelanotide (VLRX001): A compound enhancing cellular activity
Growth Outlook
  • Strategic partnership with HK Winhealth Pharma to expand in China
  • Strong pipeline with multiple promising compounds under development
  • Increasing global awareness of EPP may drive demand for SCENESSE
Financial Highlights
  • Recent quarterly revenue of AUD 36.92 million, reflecting strong market performance
  • Net income of AUD 10.44 million, showcasing profitability
  • Cash and short-term investments totaling AUD 232.91 million, indicating solid liquidity
Clinuvel Pharmaceuticals Limited is well-positioned in the biotechnology sector, focusing on unmet medical needs. The company's flagship product, SCENESSE, has established a strong market presence, particularly among EPP patients. The strategic partnership with HK Winhealth Pharma is expected to enhance market access in China, a significant growth opportunity. Financially, Clinuvel has demonstrated robust performance, with a recent quarterly revenue of AUD 36.92 million and a net income of AUD 10.44 million, reflecting effective cost management and operational efficiency. The company's liquidity is strong, with cash and short-term investments amounting to AUD 232.91 million, providing a solid foundation for future growth initiatives. Overall, Clinuvel Pharmaceuticals Limited presents a compelling opportunity for investors interested in the biotechnology sector, particularly those focused on innovative therapies for rare diseases.
AI Generated • Jul 15, 2026

Industry

Biotechnology

Sector

Health Care

CEO

Lachlan Hay

Website

www.clinuvel.com

Headquarters

Melbourne, VIC 3000, AU

CLVLF Financials

Key Financial Metrics (TTM)

Gross Margin

63.71%

Operating Margin

39.39%

Net Income Margin

33.79%

Return on Equity

13.29%

Return on Capital

18.95%

Return on Assets

12.07%

Earnings Yield

6.83%

Dividend Yield

0.54%

Payout Ratio

7.70%

Stock Overview

Market Cap

$307.51MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

50.41M

Volume

14

Avg. Volume

156.145

Financials (TTM)

Gross Profit

A$134.93M

Operating Income

A$87.03M

EBITDA

A$93.37M

Operating Cash Flow

A$64.29M

Capital Expenditure

-A$722.65K

Free Cash Flow

A$63.57M

Cash & ST Invst.

A$232.91M

Total Debt

A$340.95K

Clinuvel Pharmaceuticals Performance Analysis

Clinuvel Pharmaceuticals annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-06-30AUD 47,667,442N/A
20232023-06-30AUD 52,687,10410.5%
20242024-06-30AUD 57,789,8619.7%
20252025-06-30AUD 61,536,3236.5%
Clinuvel Pharmaceuticals sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42024-06-3070.5%
Q22024-12-31-36.3%
Q42025-06-3066.5%
Q22025-12-31-37.8%
Clinuvel Pharmaceuticals annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-06-30AUD 0.29N/A
20232023-06-30AUD 0.4035.8%
20242024-06-30AUD 0.4615.2%
20252025-06-30AUD 0.471.6%
Clinuvel Pharmaceuticals sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42024-06-30133.3%
Q22024-12-31-42.9%
Q42025-06-3057.1%
Q22025-12-31-52.3%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

A$36.92M

+12.5%

Gross Profit

A$20.74M

+22.6%

Gross Margin

56.19%

N/A

Market Cap

$307.51MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$2.82M

N/A

Employees

109

N/A

Net Income

A$10.44M

-4.5%

EBITDA

A$11.45M

-46.6%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

A$232.91M

+33.5%

Total Debt

A$340.95K

-68.1%

Accounts Receivable

A$16.58M

+26.8%

Inventory

A$8.41M

-33.0%

Long Term Debt

A$34.48K

-95.2%

Short Term Debt

A$306.47K

-13.9%

Return on Assets

12.07%

N/A

Return on Invested Capital

15.06%

N/A

Free Cash Flow

A$12.37M

-41.3%

Operating Cash Flow

A$12.52M

-52.5%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
NWBONorthwest Biotherapeutics, Inc.
$0.17+0.53%
CYDYCytoDyn Inc.
$0.20-6.54%
CMVLFCellectis S.A.
$3.47+12.66%
PTCHFPureTech Health plc
$1.60+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
NOKNokia
$9.10-0.06%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares
$7.42-0.04%
ONDSOndas
$7.80-0.02%
NUNu Holdings
$14.09-0.01%

Questions About CLVLF

What is the current price of Clinuvel Pharmaceuticals?

Clinuvel Pharmaceuticals is trading at $6.10 per share.

What is the 52-week range for Clinuvel Pharmaceuticals?

Over the past 52 weeks, Clinuvel Pharmaceuticals has traded between $6.10 and $8.60.

How much debt does Clinuvel Pharmaceuticals have?

As of the most recent reporting period, Clinuvel Pharmaceuticals reported total debt of A$346.37K.

How much cash does Clinuvel Pharmaceuticals have on hand?

Clinuvel Pharmaceuticals reported A$18.36M in cash and cash equivalents in its most recent financial results.

What is Clinuvel Pharmaceuticals’s dividend yield?

Clinuvel Pharmaceuticals currently has a dividend yield of 0.54%.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services